Patent intelligence · US
US 2017260158
QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
Patent details — US 2017260158
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 14, 2017
- Expiration
- Sep 9, 2037
- Applicant
- ABBVIE DEUTSCHLAND [DE]
- CPC classes
- A61P/2518, A61P/2528, A61P/2530
Quick answer
US 2017260158 (QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Sep 14, 2017. Expires Sep 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE DEUTSCHLAND [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/2518, A61P/2528, A61P/2530
More from ABBVIE DEUTSCHLAND [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted
Frequently asked questions
What is US patent 2017260158?
US 2017260158 (QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Sep 14, 2017. Expires Sep 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2017260158?
ABBVIE DEUTSCHLAND [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 2017260158 expire?
Our index shows an expiration date of Sep 9, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.